紫杉醇联合卡培他滨治疗老年晚期胃癌21例的临床疗效

目的评价紫杉醇（Taxol）联合卡培他滨（Capecitabine）治疗老年晚期胃癌的临床疗效和毒副反应。方法对经病理检查确诊的25例老年晚期胃癌患者，采用紫杉醇联合卡培他滨方案治疗：紫杉醇75mg／m^2，静脉滴注3h，每周1次，连用2周；卡培他滨每日2500mg／m^2，连用14天；以上化疗方案每3周重复，2个周期后评定疗效。结果可评价疗效者21例，无完全缓解（CR），部分缓解（PR）10例（47．6％），稳定（SD）5例（23．8％），进展（PD）6例（28．6％），总有效率（CR＋PR）为47．6％。中位进展期5．6个月，中位生存期8．9个月。毒副反应：骨髓抑制18例（85．7％），脱发15例（71．4％），腹泻10例（47．6％），肌肉关节痛5例（23．8％）等。所有Ⅲ度毒副反应发生6例（28．6％），元治疗相关性死亡。结论紫杉醇联合卡培他滨治疗老年晚期胃癌患者有效率较高，毒副反应可耐受，是老年晚期胃癌较理想的化疗方案。

Clinical Study on Paclitaxel Combined with Capecitabine in the Treatment of 21 Elder Patients with Advanced Gastric Cancer

Objective To evaluate the efficacy and toxicity of paclitaxel combined with capecitabine chemotherapy in the treatment of 21 elder patients with advanced gastric cancer(AGC).Methods Twenty-five elder patients with AGC were treated.The treatment schedule was paclitaxel 75 mg/m~2 for 3 hours on days 1,8 were administered by intravenous infusion and capecitabine 2 500 mg/m~2.d by oral administration for 14 days.Chemotherapy was repeated every 21days.Patients was evaluated for response every two cycles of treatment.Results Twenty-one patients were evaluated for clinical response.There was no complete response,PR 10 (47.6 %),SD 5(23.8 %),PD 6 (28.6%).The total response rate was 47.6%.Median time to progression (TTP) was 5.6 months and median overall survival time(OS) was 8.9 months.The main side effects were supperssion of bone marrow in 18 patients (85.7 %),alopecia in 15(71.4 %),diarrhea in 10 (47.6%).There was no death during the treatment.Conclusion Paclitaxel combined with capecitabine chemotherapy is an effective and well tolerated regimen in the treatment of elder AGC.It was considerable regimen in elder patients with AGC.